NCT00026169View on ClinicalTrials.gov

Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure

PHASE1CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

April 30, 2005

Conditions
Malignant NeoplasmUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

imatinib mesylate

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

44106

Case Western Reserve University, Cleveland

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00026169 - Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure | Biotech Hunter | Biotech Hunter